Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the potential role of Axitinib (AG-013736) in the
treatment of unresectable/metastatic hepatocellular carcinoma (HCC)